ARTES and Minapharm joint forces - offering packet solution for biopharmaceutical processes
Langenfeld, Germany / Cairo, Egypt, August 06, 2018
ARTES Biotechnology GmbH, Germany, and Minapharm
Pharmaceuticals and Chemical Industries S.A.E., Egypt, jointly announced today
the formation of a new strategic business pact.
Aim of this new
strategic business cooperation is to jointly out-license combinations of ARTES’
and Minapharm’s respective proprietary technologies and products to third
parties worldwide. Both partners own and control technologies for microbial and
mammalian recombinant cell lines, processes and products.
existing and established partnership among the companies bases on a successful,
long lasting business relationship. In this, ARTES acts as specialist for
microbial cell line and process
development for recombinant proteins and Minapharm on the other hand is the
major player for production and marketing of bio-pharmaceuticals in the MENA
combination of ARTES’ and Minapharm’s business intelligence and service
solutions future clients will benefit from our latest, innovative developments ”,
Dr. Michael Piontek, Managing director of ARTES stated, “and will get robust,
proven manufacturing experience and product registration.” Proven safety and
efficacy of products will team up with high yield and low cost manufacturing
“The established alliance with ARTES continuously
confirms Minapharm’s position as a regional biotech leader. Our emergence as
such contributes to a radical shift in both innovation and affordability of
biopharmaceuticals as a function of time. We have been able to demonstrate the
viability of our strategy to offer patients in the developing world with a timely
benefit of novel therapeutic proteins. Our biopharmaceutical pipeline portfolio
reflects great potential to expand our strategy and offers solutions for the management
of medical emergencies. We are glad that ARTES is sharing our vision” said
Frank Mueller, Senior Manager Biopharmaceutical Projects of MINAPHARM.
For more information regarding availability
of cell lines and process technology, please see contact below.
About ARTES Biotechnology GmbH:
Biotechnology is a pharmaceutical contract research & development
organization that provides cell line and process development for and
manufacturing of bio-pharmaceutical products. The company is a well-established
partner for many of the biggest names in the industry, with more than 20 years
of business experience, a track record of products developed for and marketed
by clients as well as safe, reliable and highly competitive microbial
production platforms. ARTES specializes in recombinant protein production,
process and vaccine development from microbial expression systems, marketing
the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression.
ARTES operates worldwide from its 850m2 S1 facilities in Langenfeld,
from where it also offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta;
Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process
development, supply of non-GMP bulk material (API) for activity and toxicity
tests and technology transfer to cGMP facilities and scale-up support.
Pharmaceuticals and Chemical Industries S.A.E.
Minapharm, headquartered in Cairo with
its production facilities in the 10th of Ramadan, is among the
leading prescription medicine companies in Egypt and the Middle East. The
company is specialized in the manufacture and marketing of innovative
pharmaceuticals and through its subsidiary Rhein-Minapharm-Biogenetics and
Probiogen in the research, development and manufacturing of biopharmaceuticals
and biosimilars. Its biotech subsidiary is focussing on the core therapeutic
areas of liver disease and thrombosis & haemostasis. With 8
therapeutic proteins already marketed and several in the pipeline, Minapharm’s
competence lies in decreasing time to market without compromising ethical and
safety standards. Currently Minapharm is building up an additional new
manufacturing facility for up to 11 m3 mammalian cell culture
focussing on disposable concepts and fermentation capacity and up 3 m3
microbial fermentation capacity in stainless steel according to EMA-GMP
standards. By combining its expertise in pharmaceuticals and leadership in
biopharmaceuticals, Minapharm, along with its worldwide strategic alliances,
contributes significantly to the quality of life of many people in the region.
Minapharm employs a collective workforce of over 1000 and is listed on the
Cairo and Alexandria stock exchange (Symbol: MIPH). For more information on Minapharm
and its products please visit www.minapharm.com and www.rhein-minapharm.com. In June 2010 Minapharm acquired the German company
Probiogen AG located in Berlin.
Dr. Melanie Piontek
ARTES Biotechnology GmbH
(0)217 327 587 12
Minapharm Pharmaceuticals and Chemical Industries